Daniel Omstead - Tekla Healthcare CEO
| HQH Stock | USD 17.38 0.13 0.75% |
CEO
Dr. Daniel R. Omstead, Ph.D., is a President, Trustee of HQ Healthcare Investors. Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC, a registered investment adviser that serves as investment adviser to the Funds. Dr. Omstead is also President of the Funds and serves on their Valuation Committee. Dr. Omstead is portfolio manager for the public and restrictedventure portfolios within the Funds. As part of these responsibilities, Dr. Omstead is a member of the Board of Directors of several portfolio companies including Decipher Biosciences Inc. and IlluminOss Medical, Inc. Prior to joining the Adviser, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company which developed therapies in the field of tissue engineering and regenerative medicine. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development, at Cytotherapeutics, Inc, a public biotech company. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in positions of increasing responsibility within the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson Johnson, and at Merck, Sharp and Dohme Research Laboratories, a division of Merck Co., Inc. Dr. Omstead provides each Fund with insights into both pharmaceutical and biotech companies. Dr. Omstead holds Ph.D. and Master Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University. He is an emeritus member of the Board of Directors of a nonprofit agency that provides emergency shelter, housing and supportive services to homeless and lowincome individuals and families in the Boston area since 2003.
| Age | 67 |
| Tenure | 21 years |
| Address | 1900 Market Street, Philadelphia, PA, United States, 19103 |
| Phone | 215 405 5700 |
| Web | https://www.teklacap.com/hqh.html |
Daniel Omstead Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Omstead against Tekla Healthcare stock is an integral part of due diligence when investing in Tekla Healthcare. Daniel Omstead insider activity provides valuable insight into whether Tekla Healthcare is net buyers or sellers over its current business cycle. Note, Tekla Healthcare insiders must abide by specific rules, including filing SEC forms every time they buy or sell Tekla Healthcare'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Omstead over three months ago Acquisition by Daniel Omstead of 5000 shares of Tekla Healthcare at 21.0108 subject to Rule 16b-3 | ||
Daniel Omstead over six months ago Acquisition by Daniel Omstead of 5950 shares of Tekla Life at 17.7489 subject to Rule 16b-3 | ||
Daniel Omstead over six months ago Disposition of 44064 shares by Daniel Omstead of Tekla Life at 19.75 subject to Rule 16b-3 | ||
Daniel Omstead over a year ago Purchase by Daniel Omstead of 10096 shares of Tekla Life |
Tekla Healthcare Management Efficiency
As of now, Tekla Healthcare's Return On Tangible Assets are decreasing as compared to previous years. The Tekla Healthcare's current Return On Assets is estimated to increase to 0.08, while Return On Capital Employed is forecasted to increase to (0). As of now, Tekla Healthcare's Asset Turnover is increasing as compared to previous years. Tekla Healthcare's management efficiency ratios could be used to measure how well Tekla Healthcare manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | CEO Age | ||
| Adam Derechin | Cohen Steers Qualityome | 56 | |
| Adam Derechin | Cohen Steers Limited | 56 | |
| Adam Derechin | Cohen Steers Reit | 56 | |
| Adam Derechin | Cohen And Steers | 56 | |
| Adam Derechin | Cohen Steers Closed | 56 | |
Management Performance
| Return On Equity | 0.0734 | ||||
| Return On Asset | -7.0E-4 |
Tekla Healthcare Inv Leadership Team
Elected by the shareholders, the Tekla Healthcare's board of directors comprises two types of representatives: Tekla Healthcare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla Healthcare's management team and ensure that shareholders' interests are well served. Tekla Healthcare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla Healthcare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher MBA, Senior Manager | ||
| Oleg Pohotsky, Independent Chairman of the Board of Trustees | ||
| Dr MS, Portfolio Manager | ||
| Lucinda Stebbins, Independent Trustee | ||
| Jeffrey Bailey, Independent Trustee | ||
| Daniel Omstead, CEO and President Trustee, Member of Valuation Committee, CEO of Hambrecht and Quist Capital Management LLC and President - HQL and President of Hambrecht and Quist Capital Management LLC and Trustee of HQL | ||
| Rakesh Jain, Independent Trustee | ||
| MBA MD, VP Mang | ||
| Frank Gentile, Senior Manager | ||
| Thomas Kent, Independent Trustee | ||
| William Reardon, Independent Trustee | ||
| Elizabeth Nabel, Independent Trustee | ||
| Laura Woodward, Chief Compliance Officer, Treasurer, Secretary |
Tekla Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tekla Healthcare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0734 | ||||
| Return On Asset | -7.0E-4 | ||||
| Profit Margin | 7.31 % | ||||
| Operating Margin | (0.01) % | ||||
| Current Valuation | 873.26 M | ||||
| Shares Outstanding | 50.62 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 26.29 % | ||||
| Number Of Shares Shorted | 74.35 K | ||||
| Price To Earning | 3.38 X |
Currently Active Assets on Macroaxis
When determining whether Tekla Healthcare Inv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tekla Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tekla Healthcare Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tekla Healthcare Investors Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Healthcare Investors. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Healthcare. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.145 | Dividend Share 1.66 | Earnings Share 1.31 | Revenue Per Share 0.197 | Quarterly Revenue Growth (0.06) |
The market value of Tekla Healthcare Inv is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Tekla Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Healthcare's market value can be influenced by many factors that don't directly affect Tekla Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.